Biolegend, 302018, APC/Cyanine7 anti-human CD16 Antibody, 100tests

CD16 is known as low affinity IgG receptor III (FcγRIII). It is expressed as two distinct forms (CD16a and CD16b). CD16a (FcγRIIIA) is a 50-65 kD polypeptide-anchored transmembrane protein. It is expressed on the surface of NK cells, activated monocytes, macrophages, and placental trophoblasts in humans. CD16b (FcγRIIIB) is a 48 kD glycosylphosphatidylinositol (GPI)-anchored protein. Its extracellular domain is over 95% homologous to that of CD16a, and it is expressed specifically on neutrophils. CD16 binds aggregated IgG or IgG-antigen complex which functions in NK cell activation, phagocytosis, and antibody-dependent cell-mediated cytotoxicity (ADCC).
100tests
Verified Reactivity: Human, Cynomolgus, Rhesus
Reported Reactivity: African Green, Baboon, Capuchin Monkey, Chimpanzee, Common Marmoset, Pigtailed Macaque, Sooty Mangabey, Squirrel Monkey
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: Human PMN cells
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration: Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: FC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Red Laser (633 nm)
Application Notes: The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation18. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections6, immunoprecipitation3, stimulation of NK cell proliferation4, blocking of phagocytosis5, and blocking of immunoglobulin binding to FcγRIII7,8. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).
Application References(PubMed link indicates BioLegend citation): Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP) Hoshino S, et al. 1991. Blood 78:3232. (Stim) Tamm A, et al. 1996. Immunol. 157:1576. (Block) Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC) Holl V, et al. 2004. J. Immunol. 173:6274. (Block) Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block) Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed Smed-Sörensen A, et al. 2008. Blood 111:5037. (Block) PubMed Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC) Rout N, et al. 2010. PLoS One 5:e9787. (FC) Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC) Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed Wu Z, et al. 2013. J. Virol. 87:7717. PubMed Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG) Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)
Product Citations: Liisborg C, et al. 2022. Acta Ophthalmol. :3. PubMed Hastie KM, et al. 2023. Cell Rep. 42:112421. PubMed Gargaro M, et al. 2022. Immunity. 55:1032. PubMed Fatehi Hassanabad A, et al. 2022. JTCVS Open. 12:118. PubMed Lee Y, et al. 2020. J Innate Immun. 1:. PubMed Jundi B, et al. 2021. JCI Insight. 6:e148866. PubMed Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed Wiernik A, et al. 2013. Clin Cancer Res. 19:3844. PubMed Masuta Y, et al. 2022. iScience. 25:105085. PubMed Bekere I, et al. 2021. PLoS Pathog. 17:e1010074. PubMed Bratcher P, et al. 2016. J Cystic Fibrosis. 15: 67-73. PubMed Hahn J, et al. 2019. Redox Biol. 26:101279. PubMed Hydes T, et al. 2017. Immun Inflamm Dis. 10.1002/iid3.190. PubMed Perry JSA, et al. 2018. Immunity. 48:923. PubMed Ong SM, et al. 2019. Front Immunol. 10:1761. PubMed Nie Y, et al. 2022. Virol J. 19:68. PubMed Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed Caduff N, et al. 2021. Cell Reports. 35(5):109056. PubMed McCracken M, et al. 2017. PLoS Pathog.. 10.1371/journal.ppat.1006487. PubMed Gleason M, et al. 2014. Blood. 123:3016. PubMed Glaros V, et al. 2021. Immunity. 54:2005. PubMed Mulder K, et al. 2021. Immunity. 54(8):1883-1900.e5. PubMed Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed Bäcker-Koduah P, et al. 2020. Ann Clin Transl Neurol. 1.422222222. PubMed Dobbs KR, et al. 2017. JCI Insight. 2:e93684. PubMed Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed Hejazi M, et al. 2022. Front Immunol. 12:798087. PubMed Warmuth S, et al. 2022. Oncoimmunology. 10:2004661. PubMed , et al. 2021. Eur J Immunol. 51:2708. PubMed Weldon A, et al. 2015. J Rheumatol. 42:749. PubMed Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed Sharma A, et al. 2020. Cell. 183(2):377-394.e21. PubMed Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed Port JR, et al. 2020. J Virol. 94:. PubMed Krishnan S, et al. 2021. Clin Exp Immunol. 203:458. PubMed Ponath V, et al. 2021. Int J Mol Sci. 22:. PubMed Levy Y, et al. 2021. iScience. 24:102711. PubMed Cirelli KM et al. 2019. Cell. 177(5):1153-1171 . PubMed Dai HS et al. 2017. Immunity. 47(1):159-170 . PubMed Ireland RE, et al. 2022. Viruses. 14:. PubMed Felices M, et al. 2018. JCI Insight. 3. PubMed Romani B, et al. 2016. J Biol Chem. 291: 2696 - 2711. PubMed Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed Buters TP, et al. 2021. Br J Clin Pharmacol. Online ahead of print. PubMed Lu H, et al. 2020. Am J Reprod Immunol. 83:. PubMed Wiedemann A, et al. 2020. Nat Commun. 3.048611111. PubMed Foote JR, et al. 2019. Front Immunol. 10:188. PubMed Corrado M, et al. 2020. Cell Metab. 32:981. PubMed Flak MB, et al. 2020. J Clin Invest. 130:359. PubMed Ehlers L, et al. 2022. Int J Mol Sci. 23:. PubMed Vallera D, et al. 2016. Clin Cancer Res. 22: 3440 - 3450. PubMed Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed Friedensohn S, et al. 2018. Front Immunol. 9:1401. PubMed
RRID: AB_314217 (BioLegend Cat. No. 302017) AB_314218 (BioLegend Cat. No. 302018)
Structure: Ig superfamily, transmembrane form (50-65 kD) or GPI-linked form (48 kD)
Distribution: NK cells, activated monocytes, macrophages, neutrophils
Function: Low affinity IgG Fc receptor, phagocytosis, ADCC
Ligand/Receptor: Aggregated IgG, IgG-antigen complex
Cell Type: Dendritic cells, Macrophages, Monocytes, Neutrophils, NK cells
Biology Area: Immunology, Innate Immunity
Molecular Family: CD Molecules, Fc Receptors
Antigen References: 1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275. 2. Stroncek D, et al. 1991. Blood 77:1572. 3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.
Gene ID: 2214
UniProt: View information about CD16 on UniProt.org
Clone: 3G8
Regulatory Status: RUO
Workshop: V NK80
Other Names: FcγRIII, Fc gamma receptor, Fc gamma receptor 3
Isotype: Mouse IgG1, κ
Q: Is our human Trustain FcX™ (cat# 422302) compatible with anti human CD16, CD32 and CD64 clones 3G8, FUN-2 and 10.1 respectively?
A: Yes